These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20189243)

  • 1. The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity.
    Karve S; Bandekar A; Ali MR; Sofou S
    Biomaterials; 2010 May; 31(15):4409-16. PubMed ID: 20189243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo.
    Bandekar A; Zhu C; Gomez A; Menzenski MZ; Sempkowski M; Sofou S
    Mol Pharm; 2013 Jan; 10(1):152-60. PubMed ID: 23134440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy.
    Karve S; Alaouie A; Zhou Y; Rotolo J; Sofou S
    Biomaterials; 2009 Oct; 30(30):6055-64. PubMed ID: 19665223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin.
    Bandekar A; Karve S; Chang MY; Mu Q; Rotolo J; Sofou S
    Biomaterials; 2012 Jun; 33(17):4345-52. PubMed ID: 22429980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
    Mamasheva E; O'Donnell C; Bandekar A; Sofou S
    Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo.
    Obata Y; Tajima S; Takeoka S
    J Control Release; 2010 Mar; 142(2):267-76. PubMed ID: 19861141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active loading and tunable release of doxorubicin from block copolymer vesicles.
    Choucair A; Soo PL; Eisenberg A
    Langmuir; 2005 Sep; 21(20):9308-13. PubMed ID: 16171366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker.
    Lavignac N; Nicholls JL; Ferruti P; Duncan R
    Macromol Biosci; 2009 May; 9(5):480-7. PubMed ID: 19016501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous domains and membrane permeability in phosphatidylcholine-phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch.
    Karve S; Bajagur Kempegowda G; Sofou S
    Langmuir; 2008 Jun; 24(11):5679-88. PubMed ID: 18471003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting.
    Munnier E; Cohen-Jonathan S; Linassier C; Douziech-Eyrolles L; Marchais H; Soucé M; Hervé K; Dubois P; Chourpa I
    Int J Pharm; 2008 Nov; 363(1-2):170-6. PubMed ID: 18687392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
    Sempkowski M; Zhu C; Menzenski MZ; Kevrekidis IG; Bruchertseifer F; Morgenstern A; Sofou S
    Langmuir; 2016 Aug; 32(33):8329-38. PubMed ID: 27468779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes.
    Zhang X; Meng L; Lu Q; Fei Z; Dyson PJ
    Biomaterials; 2009 Oct; 30(30):6041-7. PubMed ID: 19643474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents.
    Chen T; McIntosh D; He Y; Kim J; Tirrell DA; Scherrer P; Fenske DB; Sandhu AP; Cullis PR
    Mol Membr Biol; 2004; 21(6):385-93. PubMed ID: 15764368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
    Ishida T; Okada Y; Kobayashi T; Kiwada H
    Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-specific delivery of a chemotherapeutic to lung cancer cells.
    Zhou X; Chang YC; Oyama T; McGuire MJ; Brown KC
    J Am Chem Soc; 2004 Dec; 126(48):15656-7. PubMed ID: 15571383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano-scaled pH-responsive polymeric vesicles for intracellular release of doxorubicin.
    Huang WC; Chiang WH; Huang YF; Lin SC; Shih ZF; Chern CS; Chiang CS; Chiu HC
    J Drug Target; 2011 Dec; 19(10):944-53. PubMed ID: 22050402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.